Acid suppression in critically ill patients: What does the evidence support?

Pharmacotherapy

Volumn 23, Issue 10 I, 2003, Pages

  Spirt, Mitchell J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE;

CONFERENCE PAPER; CRITICAL ILLNESS; DRUG MEGADOSE; ENDOSCOPY; HELICOBACTER PYLORI; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; LENGTH OF STAY; PROPHYLAXIS; SEPSIS; STOMACH BLOOD FLOW; STRESS ULCER; TREATMENT PLANNING; UPPER GASTROINTESTINAL BLEEDING;

ADMINISTRATION, ORAL; ANTACIDS; ANTI-ULCER AGENTS; CLINICAL TRIALS; CRITICAL ILLNESS; GASTRIC ACID; GASTROINTESTINAL HEMORRHAGE; HISTAMINE H2 ANTAGONISTS; HUMANS; INJECTIONS, INTRAVENOUS; PEPTIC ULCER; PROTON PUMPS; STRESS;

EID: 0141531004     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.13.87S.31933     Document Type: Conference Paper

References (27)

1. Vorder Bruegge WF, Peura DA. Stress-related mucosal damage: review of drug therapy. J Clin Gastroenterol 1990;12(suppl 2):S35-40.
2. Konturek SJ. Prostaglandins in pathophysiology of peptic ulcer disease. Dig Dis Sci 1985;30:105S-8.
3. Zapata-Sirvent RL, Greenleaf G, Hansbrough JF, Steinsapir E. Burn injury results in decreased gastric acid production in the acute shock period. J Burn Care Rehabil 1995;16:622-6.
4. Spirt M, Guth PH, Leung FW, Randall G. Critically ill septic ICU patients have severe upper gastrointestinal mucosal ischemia. Gastroenterology 1995;108:A326.
5. Erstad BL, Barletta JF, Jacobi J, Killian AD, Kramer KM, Martin SJ. Survey of stress ulcer prophylaxis. Crit Care 1999;3:145-9.
6. Hastings PR, Skillman JJ, Bushnell LS, Silen W. Antacid titration in the prevention of acute gastrointestinal bleeding: a controlled, randomized trial in 100 critically ill patients. N Engl J Med 1978;298:1041-5.
7. Martin LF, Booth FV, Karlstadt RG, et al. Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 1993;21:19-30.
8. Ben-Menachem T, McCarthy BD, Fogel R, et al. Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Crit Care Med 1996;24:338-45.
9. Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997;42:1255-9.
10. Phillips JO, Metzler MH, Palmieri TL, Huckfeldt RE, Dahl NG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996;24:1793-800.
11. Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998;44:527-33.
12. Azevedo JR, Soares MG, Silva G, Palacio G. Prevention of stress ulcer bleeding in high risk patients: comparison of three drugs. Crit Care Med 1999;27:A41.
13. Cerra FB, Schentag JJ, McMillen M, Karwande SV, Fitzgerald GC, Leising M. Mental status, the intensive care unit, and cimetidine. Ann Surg 1982;196:565-70.
14. Pisegna JR, Martin P, McKeand W, Ohning G, Walsh JH, Paul J. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study. Am J Gastroenterol 1999;94:2874-80.
15. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994;106:60-4.
16. Barkun AN, Cockeram AW, Plourde V, Fedorak RN. Acid suppression in non-variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 1999;13:1565-84.
17. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian critical care trials group. N Engl J Med 1994;330:377-81.
18. Yacyshyn BR, Thomson AB. Critical review of acid suppression in nonvariceal, acute, upper gastrointestinal bleeding. Dig Dis 2000;18:117-28.
19. Li Y, Sha W, Nie Y, et al. Effect of intragastric pH on control of peptic ulcer bleeding. J Gastroenterol Hepatol 2000;15:148-54.
20. Birnie GG, Quigley EM, Allan G, et al. A double-blind randomized trial of cimetidine in acute upper gastrointestinal bleeding. Scand J Gastroenterol 1984;19:885-8.
21. Walt RP, Cottrell J, Mann SG, Freemantle NP, Langman MJ. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992;340:1058-62.
22. Zuckerman G, Welch R, Douglas A, et al. Controlled trial of medical therapy for active upper gastrointestinal bleeding and prevention of rebleeding. Am J Med 1984;76:361-6.
23. Labenz J, Peitz U, Leusing C, Tillenburg B, Blum AL, Börsch G. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut 1997;40:36-41.
24. Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999; 94:351-7.
25. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000;343:310-16.
26. Javid G, Masoodi I, Zargar SA, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001;111:280-4.
27. Van Rensburg CJ, Thorpe A, Warren B, et al. Intragastric pH during pantoprazole infusion of 6 mg/hour in patients with bleeding peptic ulceration. Gastroenterology 1999;116:A344.